Literature DB >> 6386879

Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum.

M E Camargo, L Silveira, J A Furuta, E P Oliveira, O A Germek.   

Abstract

An enzyme-linked immunosorbent assay was developed for measuring immunoglobulin G anti-diphtheric toxin antibodies in human serum. The assay was done in plastic plates coated with purified diphtheric toxoid. Since a straight-line relationship was found between logs of extinction values and of antibody concentrations, with a very constant slope, serum titers could be expressed as log10 of the serum dilution corresponding to a definite optical density, such as 0.5. The assay furnished highly reproducible titers on a continuous range, with coefficients of variation less than 10%. Only one or two serum dilutions were usually sufficient for serum titration. To establish correspondence of the enzyme-linked immunosorbent assay titers with biologically determined antitoxin international units, a regression equation was fitted between the respective values for 112 serum samples titrated in both tests. The enzyme-linked immunosorbent assay titer of 2.38 corresponded to an antitoxin titer of 0.01 U, which is considered as the minimal protective level. Simple to perform, economical, and precise, the immunoenzymatic assay seems to be a very practical procedure for seroepidemiological purposes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386879      PMCID: PMC271428          DOI: 10.1128/jcm.20.4.772-774.1984

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  4 in total

1.  Simple standardized enzyme-linked immunosorbent assay for human antibodies to Entamoeba histolytica.

Authors:  T M Lin; S P Halbert; C T Chiu; R Zarco
Journal:  J Clin Microbiol       Date:  1981-04       Impact factor: 5.948

2.  Normalized enzyme-linked immunosorbent assay for determining immunoglobulin G antibodies to cytomegalovirus.

Authors:  D J Kiefer; D A Phelps; S P Halbert
Journal:  J Clin Microbiol       Date:  1983-07       Impact factor: 5.948

3.  Standardized quantitative enzyme-linked immunoassay for antibodies to Toxoplasma gondii.

Authors:  T M Lin; S P Halbert; G R O'Connor
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

4.  Enzyme-linked immunosorbent assay for measurement of antibody against cytomegalovirus and rubella virus in a single serum dilution.

Authors:  A M van Loon; J T van der Logt; J van der Veen
Journal:  J Clin Pathol       Date:  1981-06       Impact factor: 3.411

  4 in total
  14 in total

1.  Determination of diphtheria toxin neutralizing antibody titers with a cell protein synthesis inhibition assay.

Authors:  E Padovan; E Papini; R Rappuoli; C Montecucco
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

2.  Immunogenicity and reactogenicity of HbOC vaccine administered simultaneously with acellular pertussis vaccine (DTaP) into either arms or thighs of infants.

Authors:  H J Schmitt; C H Wirsing von König; F Zepp; J Huff; K Jahn; P Schmidtke; C Meyer; P Habermehl; R Uhlenbusch; P Angersbach
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 3.553

3.  Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.

Authors:  G Kanra; M Ceyhan; D Vandevoorde; H Bogaerts
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

4.  Determination of neutralizing antibodies and specific immunoglobulin isotype levels in infants after vaccination against diphtheria.

Authors:  T Lagergård; B Trollfors; B A Claesson; J Karlberg; J Taranger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

5.  Immunogenicity and Reactogenicity following Primary Immunisation with a Combined DTaP-HBV Vaccine and a Haemophilus influenzae Type B Vaccine Administered by Separate or Mixed Injection.

Authors:  G Gabutti; G Bona; P Dentico; F Bamfi; K Hardt; S Majori; P Crovari
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

6.  Abnormal Newborn Screening Follow-up for Severe Combined Immunodeficiency in an Amish Cohort with Cartilage-Hair Hypoplasia.

Authors:  Ethan M Scott; Sharat Chandra; Jinzhu Li; Eric D Robinette; Miraides F Brown; Olivia K Wenger
Journal:  J Clin Immunol       Date:  2020-01-06       Impact factor: 8.317

7.  The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV).

Authors:  P Laroche; M Barrand; S C Wood; K Van Hasbrouck; J Lang; E Harzer; L Hessel
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 7.455

8.  A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia.

Authors:  Fong Seng Lim; Mia Tuang Koh; Kah Kee Tan; Poh Chong Chan; Chia Yin Chong; Yeo Wee Shung Yehudi; Yee Leong Teoh; Fakrudeen Shafi; Marjan Hezareh; Kristien Swinnen; Dorota Borys
Journal:  BMC Infect Dis       Date:  2014-10-02       Impact factor: 3.090

Review 9.  Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type B vaccine; Infanrix™ hexa: twelve years of experience in Italy.

Authors:  Vincenzo Baldo; Paolo Bonanni; Marcela Castro; Giovanni Gabutti; Elisabetta Franco; Federico Marchetti; Rosa Prato; Francesco Vitale
Journal:  Hum Vaccin Immunother       Date:  2013-09-04       Impact factor: 3.452

10.  Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants.

Authors:  Rong-Cheng Li; Teng Huang; Yanping Li; Lao-Hong Wang; Junhui Tao; Botao Fu; Guoai Si; Yi Nong; Zhaojun Mo; XueYan Liao; Ivy Luan; Haiwen Tang; Niraj Rathi; Naveen Karkada; Htay Htay Han
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.